baricitinib

Baricitinib is a prescription medicine that belongs to the class of Janus kinase inhibitors, specifically targeting JAK1 and JAK2. By inhibiting these kinases, baricitinib modulates the JAK-STAT signaling pathway used by various inflammatory cytokines, leading to reduced activity of immune cells involved in autoimmune and inflammatory diseases.

Baricitinib is approved for adults with moderate to severe rheumatoid arthritis and has also been used for psoriatic arthritis. In some regions it has been approved for adults with moderate-to-severe atopic dermatitis. It has been studied in other conditions and was investigated for use in hospitalized patients with COVID-19.

Baricitinib is taken by mouth as a tablet. It is absorbed and reaches steady-state exposure after several days. It is primarily eliminated by the kidneys, and dose adjustments are recommended for reduced kidney function and in older adults.

Safety is associated with common adverse effects including infections, especially respiratory and urinary tract infections, and increases in cholesterol. Serious infections, blood clots, and rare liver enzyme elevations have been reported. Immunosuppressive effects can lead to reduced vaccine responses; patients should be screened for latent infections prior to starting therapy. Caution with concurrent immunosuppressants and with pregnancy.

Baricitinib is marketed under the brand name Olumiant and is available in many countries for its approved indications.